John F. Paolini - Sep 1, 2023 Form 4 Insider Report for Kiniksa Pharmaceuticals, Ltd. (KNSA)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol
KNSA
Transactions as of
Sep 1, 2023
Transactions value $
-$28,308
Form type
4
Date filed
9/6/2023, 07:03 PM
Previous filing
Jul 27, 2023
Next filing
Dec 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Common Share Options Exercise +2.5K +5.96% 44.4K Sep 1, 2023 Direct F1
transaction KNSA Class A Common Share Tax liability -$13K -734 -1.65% $17.76 43.7K Sep 1, 2023 Direct
transaction KNSA Class A Common Share Options Exercise +1.73K +3.95% 45.4K Sep 2, 2023 Direct F1
transaction KNSA Class A Common Share Tax liability -$9K -507 -1.12% $17.76 44.9K Sep 2, 2023 Direct
transaction KNSA Class A Common Share Options Exercise $744 +400 +0.89% $1.86* 45.3K Sep 5, 2023 Direct F2
transaction KNSA Class A Common Share Sale -$7.01K -400 -0.88% $17.53 44.9K Sep 5, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -2.5K -25.01% $0.00 7.49K Sep 1, 2023 Class A Common Share 2.5K Direct F1, F4
transaction KNSA Restricted Share Unit Award $0 +6.5K $0.00 6.5K Sep 1, 2023 Class A Common Share 6.5K Direct F1, F5, F6
transaction KNSA Share Option Award $0 +39K $0.00 39K Sep 1, 2023 Class A Common Share 39K $17.76 Direct F6
transaction KNSA Restricted Share Unit Options Exercise $0 -1.73K -33.33% $0.00 3.45K Sep 2, 2023 Class A Common Share 1.73K Direct F1, F7
transaction KNSA Share Option Options Exercise $0 -400 -0.29% $0.00 140K Sep 5, 2023 Class A Common Share 400 $1.86 Direct F2, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
F2 This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.
F3 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.50 to $17.56. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F4 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022.
F5 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023.
F6 The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.
F7 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021.
F8 The option is fully vested and exercisable.